Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Natalucci

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of Clinical Medicine|June 24, 2022
The Impacts of the Clinical and Genetic Factors on Chronic Damage in Caucasian Systemic Lupus Erythematosus PatientsFulvia Ceccarelli, Giulio Olivieri, Carmelo Pirone, et al.
Lupus|December 16, 2020
Joint involvement influences quality of life in systemic lupus erythematosus patientsFrancesco Natalucci, Fulvia Ceccarelli, Enrica Cipriano, et al.
Arthritis Research & Therapy|August 19, 2024
Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA CohortFrancesco Natalucci, Clément Triaille, Cécile Van Mullem, et al.
Lupus|November 11, 2024
Fibromyalgia, mood disorders and chronic damage are the main determinants of worse quality of life in systemic lupus erythematosus patients: Results from a cross-sectional analysisFulvia Ceccarelli, Claudia Ciancarella, Carmelo Pirone, et al.
Biomolecules|August 26, 2022
Development of Systemic Autoimmune Diseases in Healthy Subjects Persistently Positive for Antiphospholipid Antibodies: Long-Term Follow-Up StudyFulvia Ceccarelli, Francesco Natalucci, Giulio Olivieri, et al.
Joint Bone Spine|June 25, 2021
Five-years drug survival of mycophenolate mofetil therapy in patients with systemic lupus erythematosus: Comparison between renal and non-renal involvementGiulio Olivieri, Fulvia Ceccarelli, Francesco Natalucci, et al.
Seminars in Arthritis and Rheumatism|May 4, 2017
Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessmentFulvia Ceccarelli, Carlo Perricone, Enrica Cipriano, et al.
Lupus|July 25, 2020
Caffeine intake influences disease activity and clinical phenotype in systemic lupus erythematosus patientsValeria Orefice, Fulvia Ceccarelli, Cristiana Barbati, et al.
Arthritis Research & Therapy|June 15, 2018
Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosusFulvia Ceccarelli, Carlo Perricone, Tania Colasanti, et al.
Clinical and Experimental Medicine|April 10, 2024
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohortFulvia Ceccarelli, Francesco Natalucci, Licia Picciariello, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Clinical Medicine|June 24, 2022
The Impacts of the Clinical and Genetic Factors on Chronic Damage in Caucasian Systemic Lupus Erythematosus PatientsFulvia Ceccarelli, Giulio Olivieri, Carmelo Pirone, et al.
Lupus|December 16, 2020
Joint involvement influences quality of life in systemic lupus erythematosus patientsFrancesco Natalucci, Fulvia Ceccarelli, Enrica Cipriano, et al.
Arthritis Research & Therapy|August 19, 2024
Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA CohortFrancesco Natalucci, Clément Triaille, Cécile Van Mullem, et al.
Lupus|November 11, 2024
Fibromyalgia, mood disorders and chronic damage are the main determinants of worse quality of life in systemic lupus erythematosus patients: Results from a cross-sectional analysisFulvia Ceccarelli, Claudia Ciancarella, Carmelo Pirone, et al.
Biomolecules|August 26, 2022
Development of Systemic Autoimmune Diseases in Healthy Subjects Persistently Positive for Antiphospholipid Antibodies: Long-Term Follow-Up StudyFulvia Ceccarelli, Francesco Natalucci, Giulio Olivieri, et al.
Joint Bone Spine|June 25, 2021
Five-years drug survival of mycophenolate mofetil therapy in patients with systemic lupus erythematosus: Comparison between renal and non-renal involvementGiulio Olivieri, Fulvia Ceccarelli, Francesco Natalucci, et al.
Seminars in Arthritis and Rheumatism|May 4, 2017
Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessmentFulvia Ceccarelli, Carlo Perricone, Enrica Cipriano, et al.
Lupus|July 25, 2020
Caffeine intake influences disease activity and clinical phenotype in systemic lupus erythematosus patientsValeria Orefice, Fulvia Ceccarelli, Cristiana Barbati, et al.
Arthritis Research & Therapy|June 15, 2018
Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosusFulvia Ceccarelli, Carlo Perricone, Tania Colasanti, et al.
Clinical and Experimental Medicine|April 10, 2024
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohortFulvia Ceccarelli, Francesco Natalucci, Licia Picciariello, et al.
Pageof 4